Prof. Karen M Dobos, PhD, Colorado State University, USA
Prof. Karen M Dobos graduated from Colorado State University with a PhD in Microbiology and subsequently completed fellowships at the Centers for Disease Control and Prevention, Emory University and The Mayo Clinic. Currently, she is a Professor of Microbiology, Immunology, and Pathology at Colorado State University and serves as the Scientific Director for the CSU Regional Biocontainment Laboratory and the Co-Director for the Mycobacteria Research Laboratories at CSU. Prof. Dobos's research focuses on mass spectrometry approaches for identifying novel markers associated with early-tuberculosis disease events, aiming to expedite treatment and improve patient outcomes.
Biomarkers and Animal Models for Tuberculosis Research, Diagnosis and/or Treatment Monitoring
We are proud to announce a new collection, guest edited by Subash Babu. We welcome original research articles, reviews, and case studies, aiming to enhance our understanding of TB diagnosis and treatment monitoring while fostering collaboration across disciplines to combat this global health challenge.
Image credit: © Dr_Microbe / stock.adobe.com
Combating Antibiotic Resistance and the Discovery and Development of Novel Therapeutics for Tuberculosis Control
We are proud to announce our first collection, guest edited by Christina Boucher. We welcome original research articles, reviews and case studies, addressing the critical issues surrounding antibiotic resistance in Mycobacterium tuberculosis (MTB) and the pursuit of novel therapeutic strategies.
Image credit: © [M] Dr_Microbe / Stock.adobe.com
-
Establishment of minimum protein standards for Mycobacterium tuberculosis-derived extracellular vesicles through comparison of EV enrichment methods
-
Antimicrobial susceptibility pattern in non-tuberculous mycobacteria in Iran: a systematic review
-
Mycobacteria journal launch
-
C3HeB/FeJ mice with chronic Mycobacterium avium complex pulmonary infection exhibit impaired respiratory function but not necrotising granulomatous disease
Waivers available
For articles submitted in 2024 and 2025, Mycobacteria has waivers available to offer that can be requested upon submission and allocated on acceptance. Once the standard peer review process has been completed and the Editors have decided to accept the article, authors without funding available won’t need to pay an APC. Enquire here for more information.
Aims and scope
Mycobacteria is a comprehensive, peer-reviewed publication focused on advancing mycobacterial research along with their practical applications. Topics covered include:
- basic and clinical research
- human and animal research
- drug discovery
- antimicrobial resistance
- treatment schemes
- biomarkers
- class descriptions
- soil and environmental mycobacteriology
- applications and biotechnology